These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 32066936)

  • 1. Harnessing cancer immunotherapy during the unexploited immediate perioperative period.
    Matzner P; Sandbank E; Neeman E; Zmora O; Gottumukkala V; Ben-Eliyahu S
    Nat Rev Clin Oncol; 2020 May; 17(5):313-326. PubMed ID: 32066936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of cancer: targeting cancer during active disease or during dormancy?
    Shah SA; Zarei M; Manjili SH; Guruli G; Wang XY; Manjili MH
    Immunotherapy; 2017 Sep; 9(11):943-949. PubMed ID: 29338608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
    Yu WD; Sun G; Li J; Xu J; Wang X
    Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting the critical perioperative period to improve long-term cancer outcomes.
    Horowitz M; Neeman E; Sharon E; Ben-Eliyahu S
    Nat Rev Clin Oncol; 2015 Apr; 12(4):213-26. PubMed ID: 25601442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy.
    Park SY; Kim IS
    Cancer Lett; 2019 Jun; 452():51-58. PubMed ID: 30910590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity.
    Bakos O; Lawson C; Rouleau S; Tai LH
    J Immunother Cancer; 2018 Sep; 6(1):86. PubMed ID: 30176921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches.
    Goradel NH; Mohajel N; Malekshahi ZV; Jahangiri S; Najafi M; Farhood B; Mortezaee K; Negahdari B; Arashkia A
    J Cell Physiol; 2019 Jun; 234(6):8636-8646. PubMed ID: 30515798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
    Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
    Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
    EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
    Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
    Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
    Alvarez-Breckenridge C; Giobbie-Hurder A; Gill CM; Bertalan M; Stocking J; Kaplan A; Nayyar N; Lawrence DP; Flaherty KT; Shih HA; Oh K; Batchelor TT; Cahill DP; Sullivan R; Brastianos PK
    Oncologist; 2019 May; 24(5):671-679. PubMed ID: 30796152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Immunotherapies: What the Perioperative Physician Needs to Know.
    Ackerman RS; Muncey AR; Aldawoodi NN; Kotha R; Getting REG
    Curr Oncol Rep; 2022 Apr; 24(4):399-414. PubMed ID: 35141856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic virus immunotherapy: future prospects for oncology.
    Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
    J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer].
    Schmid SC; Koll FJ; Beckert F; Seitz AK
    Urologe A; 2020 Jul; 59(7):790-796. PubMed ID: 32472221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
    Zou P; Tang R; Luo M
    Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative systemic therapy for bladder cancer.
    Eulitt PJ; Bjurlin MA; Milowsky MI
    Curr Opin Urol; 2019 May; 29(3):220-226. PubMed ID: 30855376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side effects of immunotherapy: a constant challenge for oncologists.
    Scotté F; Ratta R; Beuzeboc P
    Curr Opin Oncol; 2019 Jul; 31(4):280-285. PubMed ID: 30925538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.